Cellphone System Makes DNA Detection Affordable and Portable – Bioscience Technology

In a proof-of-concept study, researchers from the University of California Los Angeles showed that they could detect the presence of DNA molecules using a new dye mixture and the sensors and optics of cellphones. The new system reads light created by the detector dye mixture, with a 10-times brighter signal, at a fraction of the cost of traditional laboratory equipment.

Typical diagnostic tests, such as ones for infectious diseases and genetic disorders, rely on amplifying the number of disease related nucleic acids like DNA or RNA with fluorescent dyes.

However, intercalator dyes, as they are called, which are small changes in light emitted from molecules that associate with DNA, are too subtle and unstable for regular cellphone camera sensors.

To address the problem, researchers including Aydogan Ozcan, Chancellors Professor of Electrical Engineering and Bioengineering, and Dino Di Carlo, professor of bioengineering and mechanical and aerospace engineering, found that by including a chemical additive they could stabilize the intercalator dyes and significantly increase the fluorescent signal above the background light level. This made it possible to incorporate the test with inexpensive cellphone based detection methods.

The new system was used in a process called loop-mediated isothermal amplification (LAMP), with DNA from lambda phage as the target molecule, and achieved results that were comparable to traditional laboratory equipment that costs tens of thousands of dollars more.

The team also developed a handheld reader to enable a cellphone to pick up on the light produced from dyes associated with amplified DNA while they were in well plates. The reader uses a cost-effective and portable fiber optic bundle that routed each well in the plates signal to a unique site of the camera sensor. This too produced results comparable to a standard benchtop reader, but at a significantly lower cost.

The researchers believe this reader could have applications for use with other fluorescence-based diagnostic tests and could be especially valuable in resource-limited settings.

Currently nucleic acid amplification tests have issues generating a stable and high signal, which often necessitates the use of calibration dyes and samples which can be limiting for point-of-care use, Di Carlo said in a prepared statement. The unique dye combination overcomes these issues and is able to generate a thermally stable signal, with a much higher signal to noise ratio. The DNA amplification curves we see look beautiful without any of the normalization and calibration which is usually performed, to get to the point that we start at.

The team, including lead author Janay Kong, a Ph.D. student in bioengineering, suggest that the novel dye combinations could be used in a number of other amplification tests because it can be universally used to detect any nucleic acid amplification.

Up next they plan to test the system on complex clinical samples and nucleic acids linked with pathogens like influenza.

The findings were reported in ACS Nano.

Read the original:
Cellphone System Makes DNA Detection Affordable and Portable - Bioscience Technology

UCLA researchers make DNA detection portable, affordable using cellphones – University of California

Researchers at UCLA have developed an improved method to detect the presence of DNA biomarkers of disease that is compatible with use outside of a hospital or lab setting. The new technique leverages the sensors and optics of cellphones to read light produced by a new detector dye mixture that reports the presence of DNA molecules with a signal that is more than 10-times brighter.

Nucleic acids, such as DNA or RNA, are used in tests for infectious diseases, genetic disorders, cancer mutations that can be targeted by specific drugs, and fetal abnormality tests. The samples used in standard diagnostic tests typically contain only tiny amounts of a diseases related nucleic acids. To assist optical detection, clinicians amplify the number of nucleic acids making them easier to find with the fluorescent dyes.

Both the amplification and the optical detection steps have in the past required costly and bulky equipment, largely limiting their use to laboratories.

In a studypublished onlinein the journal ACS Nano, researchers from three UCLA entities the Henry Samueli School of Engineering and Applied Science, the California NanoSystems Institute, and the David Geffen School of Medicine showed how to take detection out of the lab and for a fraction of the cost.

The collaborative team of researchers included lead author Janay Kong, a UCLA Ph.D. student in bioengineering; Qingshan Wei, a post-doctoral researcher in electrical engineering; Aydogan Ozcan, Chancellors Professor of Electrical Engineering and Bioengineering; Dino Di Carlo, professor of bioengineering and mechanical and aerospace engineering; andOmai Garner, assistant professor of pathology and medicine at the David Geffen School of Medicine at UCLA.

The UCLA researchers focused on the challenges with low-cost optical detection. Small changes in light emitted from molecules that associate with DNA, called intercalator dyes, are used to identify DNA amplification, but these dyes are unstable and their changes are too dim for standard cellphone camera sensors.

But the team discovered an additive that stabilized the intercalator dyes and generated a large increase in fluorescent signal above the background light level, enabling the test to be integrated with inexpensive cellphone based detection methods. The combined novel dye/cellphone reader system achieved comparable results to equipment costing tens of thousands of dollars more.

To adapt a cellphone to detect the light produced from dyes associated with amplified DNA while those samples are in standard laboratory containers, such as well plates, the team developed a cost-effective, field-portable fiber optic bundle. The fibers in the bundle routed the signal from each well in the plate to a unique location of the camera sensor area. This handheld reader is able to provide comparable results to standard benchtop readers, but at a fraction of the cost, which the authors suggest is a promising sign that the reader could be applied to other fluorescence-based diagnostic tests.

Currently nucleic acid amplification tests have issues generating a stable and high signal, which often necessitates the use of calibration dyes and samples which can be limiting for point-of-care use, Di Carlo said. The unique dye combination overcomes these issues and is able to generate a thermally stable signal, with a much higher signal to noise ratio. The DNA amplification curves we see look beautiful without any of the normalization and calibration, which is usually performed, to get to the point that we start at.

Additionally, the authors emphasized that the dye combinations discovered should be able to be used universally to detect any nucleic acid amplification, allowing for their use in a multitude of other amplification approaches and tests.

The team demonstrated the approach using a process called loop-mediated isothermal amplification, or LAMP, with DNA from lambda phage as the target molecule, as a proof of concept, and now plan to adapt the assay to complex clinical samples and nucleic acids associated with pathogens such as influenza.

The newest demonstration is part of a suite of technologies aimed at democratizing disease diagnosis developed by the UCLA team. Includinglow-cost optical readout and diagnostics based on consumer-electronic devices,microfluidic-based automationandmolecular assays leveraging DNA nanotechnology.

This interdisciplinary work was supported through a team science grant from the National Science Foundation Emerging Frontiers in Research and Innovation program.

Read more here:
UCLA researchers make DNA detection portable, affordable using cellphones - University of California

Rohit Bhargava: My path to Illinois – University of Illinois News

I grew up in Jaipur, India, a city that is well-known for its architecture. My father is an architect, and I grew up helping him, looking at plans and making blueprints. I was always interested in building things.

During my grade 10 exams, I made a bet with my parents that if I scored the highest points in the school, I could get a motorcycle. I earned the motorcycle and gained a lifelong love for speed.

Photo courtesy of Rohit Bhargava. Map by Michael Vincent

Edit embedded media in the Files Tab and re-insert as needed.

In India, all high schoolers take one exam to qualify for the major colleges in engineering. I ranked fourth in the country for architecture. This delighted my father, of course. However, I surprised myself and everyone else by choosing to pursue chemical engineering instead.

As an undergraduate, I appreciated that the world around us was composed of important molecules which remain largely hidden from our eyes that can only sense shape and color. In my doctoral studies, I was inspired to develop a microscope that could measure molecular composition in addition to shape a technique we now call chemical imaging.

After graduating, I went to the National Institutes of Health as a postdoctoral fellow, where we used chemical imaging to study cancer. I grew interested in cancer and how it is diagnosed. I was convinced that there was a better way than how we diagnosed it back then.

Cancer is different from every other medical condition. It strikes without warning, at any age, with amazing frequency. Forty percent of people will develop some form of cancer in their lifetime.

Photo by National Cancer Institute on Unsplash

Edit embedded media in the Files Tab and re-insert as needed.

As I learned more, I could imagine many ways engineering could be applied to cancer optics, lasers, 3D printing but where could this kind of multidisciplinary innovation thrive?

These ideas could only be practiced at an interdisciplinary university, because cancer knows no boundaries. So in 2005, when I learned that Illinois had formed a new department of bioengineering, I applied right away. Two months later, I became the first external hire in the department.

Illinois technology has transformed lives, from the transistor to the LED, the MRI and the web browser. I knew we had the science and people to transform cancer too, if only we could bring them together. In 2010, I led the formation of the Cancer Community at Illinois on this vision, with no blueprint to guide us.

As the concept of converging engineering, technology and health gained momentum and support on campus, I served on committees guiding the development of the engineering-based Carle Illinois College of Medicine and the Interdisciplinary Health Sciences Institute. The Cancer Center at Illinois was formalized as a campuswide institute in 2018, and I am honored to continue leading the effort as its first director.

Our mission is to translate engineering and basic science innovations to cancer care. This focus sets us apart from other cancer centers in the nation, whose guiding focus is clinical care.

For a century, the gold standard of diagnosis has been to add chemical dyes to biopsies, and then a pathologist looks for abnormalities. Its time-consuming and very subjective. My group has pioneered chemical imaging techniques using light instead of dyes, truly seeing cancer in colors that we were not able to previously.

Breast cancer tissue imaged in unseen colors. On the left is the standard method using dyes. On the right is a new technique we developed that gives standard microscopes state-of-the-art infrared capabilities, with results in 30 minutes. The pink is cancer.

Images courtesy of Rohit Bhargava

Edit embedded media in the Files Tab and re-insert as needed.

We are developing artificial intelligence to analyze data from our imaging tools so that we can quickly assess the severity of disease. Tomorrow, we will use quantum computing on these data to understand cancer for individual patients.

We are developing 3D-printing techniques to create tissue scaffolds and tumor environments with a variety of materials, from plastics to sugars that dissolve away.

Imagine a physician trying to figure out which treatment would work best for a patient. Today, we try formulaic treatments on a patient and only find out weeks later whether the treatment was effective. Instead, we want to print out a replica of a patients tumor and its surrounding tissues using their own cells and testing different drugs. We could then give them a precise, individualized treatment plan that works from day one.

Traditional 3D printers lay down layers of plastic on top of each other. Our printer can essentially draw in midair, creating structures that mimic complex biological frameworks.

We have begun the process of obtaining National Cancer Institute designation. We would be the first NCI-designated basic center focused on technology. We also would be the first new basic center designated since 1987.

We already are having an impact through collaborations with our clinical partners: the University of Illinois at Chicago, the Mayo Clinic and Carle Health. We can make an even greater impact with the Discovery Partners Institute. Cancer research can be a driver of DPI, and DPI is the gateway to getting our cancer technology to the world.

CCIL scientists are developing tools for precision medicine, real-time surgical imaging, early detection, new drugs and more. We support this progress with educational programs and resource development. Pictured: Professor Rohit Bhargava and graduate student Craig Richard.

Photo by L. Brian Stauffer

Edit embedded media in the Files Tab and re-insert as needed.

Whenever anyone thinks of technology in cancer, I want them to think of Illinois. I believe that technology can make cancer care more humane. Our tools can help eliminate guesswork for physicians, eliminate waiting for patients, and accelerate the search for cures to enable precise and personally fulfilling care for everyone, regardless of their socio-economic status. At Illinois, we are proud of the ways weve changed the world. Now we have a chance to revolutionize the cancer technology industry with the Cancer Center at Illinois.

After all this time, I'm still interested in building things.

Although he ultimately did not follow his fathers footsteps into architecture, there is one building that Bhargava is excited to help design: The future CCIL building, part of the campus strategic master plan.

Photo courtesy of the University of Illinois at Urbana-Champaign. Graphic elements by Michael Vincent

Edit embedded media in the Files Tab and re-insert as needed.

Read the original here:
Rohit Bhargava: My path to Illinois - University of Illinois News

Injections to become pills, in vision of Harvard-launched startup – Harvard School of Engineering and Applied Sciences

A new startup, i2O Therapeutics, has launched to commercialize innovations developed at Harvard University that may one day enable patients and clinicians to give up syringes in favor of pills.

Using ionic liquid technologies developed in the lab of Harvard bioengineer Samir Mitragotri, biologic therapies that would normally need to be delivered via needle may be reformulated and encapsulated as pills for oral delivery. Harvards Office of Technology Development has granted i2O Therapeutics an exclusive license to the technology, to develop safe and effective oral formulations for a range of biologics, large molecules, and peptide-based pharmaceuticals. The company has raised $4M in seed funding from Sanofi Ventures and the JDRF T1D Fund to advance its mission, and will initially focus on developing formulations for GLP1 analogs, glucagon-like peptides that help balance glucose levels to treat diabetes.

Our technology has the potential to enable the oral delivery of high-value drugs in a safer, more effective and patient-friendly way and also by easing the treatment burden for dozens of therapeutics that were previously restricted to intravenous or subcutaneous delivery, said Mitragotri, who is Hiller Professor of Bioengineering and Hansjorg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) and a Core Faculty member at Harvards Wyss Institute for Biologically Inspired Engineering.

Three main obstacles typically prevent the administration of protein drugs by mouth. Digestive enzymes in the gut can easily destabilize the molecules; a layer of thin mucus in the gut presents a physical barrier; and the cells lining the wall of the gut have extremely tight junctions that can prevent the transport of proteins. The Mitragotri Labs innovations have been shown to overcome all three.

In a 2018 publication in the Proceedings of the National Academy of Sciences, Mitragotris lab demonstrated the successful oral delivery of insulin, in animal models, using ionic liquids. We showed that we can formulate insulin in the ionic liquid, we can stabilize it, and we can get substantial fractions of the delivered dose into blood circulation, Mitragotri said. The lab received funding and strategic advising from Harvards Blavatnik Biomedical Accelerator to further advance and validate the technology. The translational funding from the Blavatnik Accelerator was very significant, very important to the development of these innovations, Mitragotri said.

The ionic liquids developed in Mitragotris lab are essentially liquid salts, composed of small-ion ingredients that are generally regarded as safe. By choosing the right ions, you can control the properties, so you can make them more viscous, less viscous, more tissue penetrating, or inert, he explained. We pair these formulations up with specific drugs, and we have shown in the lab that a variety of drugs can be delivered, like insulin, including other peptides, small molecules, and antibodies.

The primary indications are likely to include diabetes, autoimmune disease, and oncology. Those are the key areas where we see this platform making a strong impact, Mitragotri added.

The technology has the potential to ease the burden of treatment for numerous conditions and improve patients overall experience.

For millions of patients worldwide, a pill would be more attractive than a therapy that needs to be injected. Oral delivery of biologics is a challenge that many engineers and chemists have tried to address, and one that becomes more urgent as modalities trend toward peptide, antibody, and mRNA therapies, said Isaac Kohlberg, Harvards Senior Associate Provost and Chief Technology Development Officer. Through their years of research efforts and translational support from the Blavatnik Biomedical Accelerator, the Mitragotri Lab has created a unique and innovative drug delivery platform with compelling validational results. Were pleased that through the launch of this startup, the team will be able to move it to the next stage of development and toward the clinic.

Several entrepreneurial members of Mitragotris Harvard lab have taken up roles at the company. Tyler Brown, PhD 19, completed his doctoral studies in bioengineering at Harvard SEAS; he is now a Principal Scientist at i2O. Kelly Ibsen, PhD, was a research fellow in the Mitragotri Lab and is now the companys Director of Research and Strategic Project Management. Mitragotri is a co-founder and board member of i2O and will be a scientific advisor to the new company, which is currently housed at the Pagliuca Harvard Life Lab.

Its extremely satisfying to see the technology make this jump from an academic discovery to a company that is moving it forward towards clinical application, Mitragotri said. That's what really drives us as bioengineers, to see our technologies eventually reach and help patients.

Excerpt from:
Injections to become pills, in vision of Harvard-launched startup - Harvard School of Engineering and Applied Sciences

Combating Wear and Tear – Newswise – Newswise (press release)

Newswise By the time someone realizes they damaged a ligament, tendon or cartilage from too much exercise or other types of physical activity, its too late. The tissue is stretched and torn and the person is writhing in pain.

But a team of researchers led by University of Utah bioengineering professors Jeffrey Weiss and Michael Yu has discovered that damage to collagen, the main building block of all human tissue, can occur much earlier at a molecular level from too much physical stress, alerting doctors and scientists that a patient is on the path to major tissue damage and pain.

This could be especially helpful for some who want to know earlier if they are developing diseases such as arthritis or for athletes who want to know if repeated stress on their bodies is taking a toll.

The scientific value of this is high because collagen is everywhere, Yu says. When we are talking about this mechanical damage, were talking about cartilage and tendons and even heart valves that move all the time. There are so many tissues which involve collagen that can go bad mechanically. This issue is important for understanding many injuries and diseases.

The teams research, funded by the National Institutes of Health, was published this week in the latest issue of Nature Communications.

Before, scientists thought collagen which are strands of protein braided into a ropelike structure that give tissue its strength and stiffness would just stretch or slide by each other during repeated stress. They never knew if they actually got damaged. As a result, patients who put repeated stress on their body would not know if they were on the road to something worse from tough physical activity.

But now the team discovered that the collagen molecule does in fact get unraveled at a molecular level before complete failure of the tissue occurs. This type of minor damage, called subfailure damage, is associated with common injuries to connective tissues such as ligament and meniscus tears and various types of tendinitis such as tennis elbow and rotator cuff tendinopathy.

Accumulation of subfailure damage can go on for a long time with no catastrophic failure, but repeated damage results in inflammation, says Weiss, So this vicious cycle continues, the inflammation breaks down the tissue, making it more susceptible to damage, which then can result in a massive tear.

The team used a new probe called collagen hybridizing peptide (CHP), a tiny version of collagen that binds to unraveled strands of damaged collagen, to figure out where and how much damage has occurred in overloaded tendons.

This paves the way for medical researchers to use CHP probes in the future as a way of diagnosing if a person has damaged collagen and if so, how much and where, before a massive tear happens. Weiss and Yu also believe it can be used as a way to deliver drugs straight to the damaged tissue because the CHP targets only the damaged collagen. Finally, it will tell doctors even more about what happens to our bodies during repeated physical activity.

A fundamental understanding of the loads and strain that cause molecular damage has eluded us until now, says Weiss. Our findings can translate into recommendations for athletes on how to train or what rehabilitation protocols people who are injured can use.

Co-authors include researchers in the Department of Bioengineering at the University of Utah (Jared Zitnay, Yang Li, Boi Hoa San and Shawn Reese) and the Department of Civil and Environmental Engineering at Massachusetts Institute of Technology (Markus Buehler, Zhao Qin and Baptiste DePalle. The CHP probe has been commercialized by 3Helix, Inc, based in Salt Lake City, Utah.

This news release and photos may be downloaded from: http://unews.utah.edu

View original post here:
Combating Wear and Tear - Newswise - Newswise (press release)

Biomedical and bioengineering center at UNH committed to cutting-edge research – The Union Leader

DURHAM At the University of New Hampshires Center of Integrated Biomedical and Bioengineering Research, students and staff are working on breakthroughs in rare cancers, autism, memory and tissue engineering.

UNH earned the Carnegie Classification of Institutions of Higher Education R1 distinction in December 2018.

According to school officials, the biomedical and bioengineering center provides equipment and training for the next generation of biological scientists and will help maintain and improve the colleges overall research designation.

Were providing the environment so that the biological sciences are holding their own with maintaining that R1 designation, said Rick Cote, director of the center.

The center is funded by a five-year, $10 million grant from the National Institutes of Health. That funding can be extended up to 15 years, Cote said.

Cote said the center allows an impressive number of students to participate in research compared to other universities. Undergraduate and graduate students work in the labs.

The experiences that students get in a research environment, not just a teaching lab, but in a research environment, really make them highly competitive for jobs in the biotech industry, the pharmaceutical industry and biomanufacturing, Cote said.

Travis Fischer of Candia is a junior studying biochemisty. He said having access to hands-on research is why he chose UNH over other colleges.

Fischer is part of the Honors Program. He works with associate professor of immunology Sherine Elsawa as she works to understand rare cancers.

When I graduate from here, hopefully with my bachelors, I want to go to grad school doing sort of the same thing, looking at cancer, other disease, research-based fields. And then after that, I want to go into industry or continue conducting my own research, Fischer said.

Elsawa is currently looking at how inflammation and cancer might be connected.

A little bit of inflammation is a good thing because if you have a viral infection or a bacterial infection, the body produces these inflammatory proteins to alert the immune system to come and take care of this problem. But if its not regulated, then it can be a problem, Elsawa explained.

Ph.D. candidate Ashley Sterpka, who has a bachelors degree in biology and a masters in science education from Syracuse University, is working with associate professor of neurobiology Xuanmao Chen to understand autism and memory.

Chen and his team published a study last year that may help answer the question of why autism is four times more common in boys than girls. They identified and characterized the connection of certain proteins in the brain to autism spectrum disorders, according to UNH Today.

Now, Sterpka is looking into astrocytes in the brain, which help neurons connect.

In the cases of neurodegenerative diseases like multiple sclerosis and Alzheimers, brain injury, epilepsy, and a whole plethora of just brain illnesses, astrocytes become reactive and when they become reactive they change shape and they change function, too, Sterpka said.

Ph.D. student Seth Edwards, who has a bachelors degree in chemical engineering from the University of Rochester and lives in Hampton, was a co-author on the study associate professor of chemical engineering Kyung Jae Jeong published in ACS Applied Bio Materials in October 2018.

Jeong and his team had created a low-cost, injectable hydrogel that could help wounds heal faster.

They are currently working on injectable hydrogels for bone and cardiac engineering.

Were looking to apply our systems to those, among other applications, Edwards said.

Other current research projects at the Center of Integrated Biomedical and Bioengineering Research include work on nicotine stimulus and identification of major depressive disorders, according to UNHs website.

Cote said the center has approximately 15 faculty members and 75 students.

Go here to see the original:
Biomedical and bioengineering center at UNH committed to cutting-edge research - The Union Leader

Rice University students and staff team up with Canadian company to make low-cost ventilators – InnovationMap

When foreigners invest in emerging markets, the prospect for those markets' local businesses looks bright. The payoffs for a country's companies can range from injections of foreign capital to better managerial talent, technological sophistication and international know-how. But does foreign investment ever push local firms to venture into international projects of their own?

Rice Business professor Haiyang Li looked closely at the ripple effects of foreign investments, and concluded it all depends on the local businesses' adaptability. That and their appetite for risk.

Together with Xiwei Yi of Peking University and Geng Cui of Lingan University, Hong Kong, Li launched a large-scale study of Chinese manufacturers to better understand how multinational investment in domestic companies influences the global market.

The subject was ripe for analysis. Over the past decade, more and more companies in China and other emerging markets have been testing the waters of direct investment in other countries in sectors as varied as food and beverages, apparel, electronics and transportation equipment.

Li's team hypothesized that these emerging market companies were leveraging benefits that foreign investment had ferried into their home markets. This investment, the researchers theorized, had brought in useful resources and skills, which helped ease the local companies into international business markets.

To confirm this, the team needed to test whether the converse was true: Might information gained from foreign investors actually dull a local firm's interest in branching out overseas? Maybe the risks of that type of venture which are higher for firms in emerging markets would seem too stark.

To find out, the researchers first vetted the literature on inward and outward investment activities. How, they wanted to know, did domestic firms interact with foreign players in the technology or product importing process? In equipment manufacturing? In franchising and licensing, mergers and acquisitions and activities such as setting up subsidiaries?

Working with a global research company, Li and his colleagues next surveyed 1,500 Chinese businesses in the food, clothing, electronics and vehicle industries. (Firms in finance, banking, natural resources and business services were ruled out because of their government ties, and also because such organizations usually use fewer resources, which made them harder to evaluate.)

Each company that took part in the survey rated how much they engaged with foreign investors in activities such as importing products and services or forming joint ventures. They also indicated if dealing with foreign direct investment had brought them foreign capital, advanced manufacturing know-how, managerial experience or competitive insight into overseas business.

The researchers also measured the "fungibility" of these firms' resources in other words, how easily could their organizational, cultural and technological resources be adapted to various geographical settings?

Finally, managers rated how risk-prone they thought their firms were.

After Li and his coauthors processed the answers, they found several links between foreign investment in domestic firms and local companies' internationalization efforts.

First, there was a positive relationship between the local gains from foreign investment and a firm's interest in internationalization projects. While this effect was indirect, it was amplified when foreign investment gave a firm new capabilities that made it more adaptable. In other words, the Chinese companies whose contact with foreign multinationals made them more adaptable in general were better positioned to prosper in ventures abroad.

This stands to reason, the researchers note. That's because by its very nature foreign investment sparks awareness of new opportunities: every business trip, plant visit or negotiation with foreign partners is a hands-on lesson in international trade.

But the researchers also uncovered a significant downside to foreign investment for local Chinese firms. When a project was considered high-risk, such as a merger or establishment of a wholly owned subsidiary, the local firms were less prone to venture abroad. This adverse effect was worse for firms that labeled themselves risk-averse, probably because exposure to foreign investors only made the risks of internationalizing clearer.

These findings add important detail to the way foreign investment can affect their local partners' own international plans for good and ill. Already, businesses in emerging markets are used to optimizing resources, wrangling diverse idioms and artisans and adapting logistically to get their products to market. That nimbleness, Li and his colleagues propose, should also be seen as a globalization tool. For businesses in emerging markets, the researchers conclude, day-to-day technical ability is actually less important than cultural and organizational flexibility and applying lessons learned from foreign investors to their own projects abroad.

In other words, for firms in emerging markets, globalization is not just a path to new markets. It's a way to study interactions with foreign firms while on their home turf and learn how to apply those lessons abroad.

------

This story originally ran on Rice Business Wisdom.

Haiyang Li is Area Coordinator and Professor of Strategic Management at Jones Graduate School of Business at Rice University.

Read this article:
Rice University students and staff team up with Canadian company to make low-cost ventilators - InnovationMap

Valentine’s Day Matters of the Heart, Biopharma-Style – PharmaLive

On Valentines Day, BioSpace would be remiss not to mention, er, matters of the heart. There are reportedly 59 life sciences companies or organizations worldwide that focus on the cardiovascular system, ranging from the Aab Cardiovascular Research Institute based in West Henrietta, New York to XyloCor Therapeutics, headquartered in Philadelphia, Pennsylvania. That number is probably low.

But no matter how you look at it, there is a significant amount of work being done on cardiovascular diseases. Heres a look at just some of the recent news.

On January 28, 2020, the U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Companys Trijardy XR for lowering blood sugar in adults with type 2 diabetes.

Trijardy XR is a triple-combination pill that includes Jardiance (empagliflozin), Tradjenta (linagliptin) and metformin hydrochloride extended release. It is prescribed along with diet and exercise for decreasing blood glucose levels in type 2 diabetes.

In the U.S., Jardiance and Radjenta are once-daily tablet used to treat adults with type 2 diabetes. Jardiance has also been approved to decrease the risk of cardiovascular death in adults with type 2 diabetes with known cardiovascular disease.

On February 3, 2020, researchers with the University of South Florida (USF Health) identified key mechanisms behind the loss of capillaries, which drives numerous diseases, including high blood pressure, diabetes, malignant cancer and a variety of cardiovascular and neurodegenerative diseases.

Capillary regression (loss) is an underappreciated, yet profound, feature of many diseases, especially those affecting organs requiring a lot of oxygen to work properly, said George Davis, professor of molecular pharmacology and physiology at the USF Morsani College of Medicine in Tampa, Florida. If we know how blood vessels are altered or begin to break down, we should be able to fix it pharmacologically.

Davis led a research project that identified the three major proinflammatory mediators that drive capillary loss. They published the research in the journal Arteriosclerosis, Thrombosis, and Vascular Biology.

The mediators are interleukin-1 beta (IL-1), tumor necrosis factor alpha (TNFalpha) and thrombin). They found that individually and even more so when combined, these directly drive capillary regression. They also identified drug combinations that can neutralize antibodies that specifically block IL-1 and TNFalpha, that can interfere with this capillary loss.

On January 27, 2020, AstraZeneca announced that its Brilinta (ticagrelor) hit the primary endpoint in the Phase III THALES trial in stroke. The study showed that 90mg of Brilinta twice a day and taken with aspirin for 30 days, provided a statistically significant and clinically meaningful decrease in the risk of stroke and death compared to aspirin alone. The trial was run in more than 11,000 patients who had a minor acute ischemic stroke or high-risk transient ischemic attack (TIA) in 24 hours before the beginning of treatment.

Results of the Phase III THALES trial showed Brilinta, in combination with aspirin, improved outcomes in patients who had experienced a minor acute ischemic stroke or high-risk transient ischemic attack, said Mene Pangalos, executive vice president, BioPharmaceuticals R&D. We look forward to sharing the detailed result with health authorities.

Earlier that month, however, the company announced that after a recommendation from an independent Data Monitoring Committee, it was abandoning its Phase III STRENGTH trial for Epanova (omega-3 carboxylic acids) for mixed dyslipidemia (MDL). Epanova is a fish oil-derived combination of free fatty acids composed mostly of EPA and DHA. It was approved in the U.S. as an adjunct to diet to decrease triglyceride levels in adults with severe high triglycerides. That indication wasnt changed by the data from the STRENGTH trial.

AstraZenecas exit from the fish oil drug trial largely leaves Amarin Corporations Vascepa (icosapent ethyl) as the only fish-oil drug to not only treat high triglycerides, but to decrease the risk of first and subsequent heart attacks, strokes and heart problems. In its clinical trials, Vascepa decrease those risks by 30%.

Although derived from fish, Vascepa is not fish oil. It is made up of the omega-3 acid (EPA) in ethyl-ester form. It was designated a new chemical entity by the FDA,

The same day AstraZeneca made their announcement, another company in the market space, Acasti Pharma, also reported a failure. Its own fish oil-based candidate, CaPre (omega-3 phospholipid) for severe hypertriglyceridemia, announced topline data from its Phase III TRILOGY 1 trial. Although it reported a 30.5% median reduction in triglyceride levels compared to 27.5% in the placebo group at 12 weeks, as well as a 42.2% decrease in patients on background statins compared to 31.5%, because of an unexpectedly large placebo response, the trial did not reach statistical significance.

And as long as were belaboring the Matters of the Heart theme, in mid-December 2019, Vancouver, British Columbia-based Novoheart signed an exclusive licensing deal with Harvard Universitys Office of Technology Development.

The deal allows Novoheart to merge its MyHeart Platform with Harvards tissue-engineered scale model of the heart ventricle and bioreactor technology. Novoheart invented and commercialized the first and only human heart-in-a-jar model for drug discovery and development.

Harvards valved bioreactor technology was engineered in Kevin Kit Parkers laboratory. He is the Tarr Family Professor of Bioengineering and Applied Physics at Harvard A. Paulson School of Engineering and Applied Sciences.

The two institutions expect that the merged technology will result in a next-generation human heart-in-a-jar that will be a superior human heart model for disease modeling, drug discovery and development with unmatched biofidelity as well as significantly enhanced predictive accuracy, capacity and versatility.

In addition to developing various bioengineered human heart constructs, Novoheart wants to develop the technology into transplantable grafts for cell-based regenerative heart therapies. The companys various products include Human Ventricular Cardiomyocytes (hvCM), Cardiac Anisotropic Sheet (hvCAS), Cardiac Tissue Strip (hvCTS), and Cardiac Organoid Chamber (hvCOC). It also offers consultation and screening and phenotyping services using its 2D or 3D tissue assays.

On November 26, Novoheart announced a collaboration with AstraZeneca to develop the worlds first human-specific in vitro, functional model of heart failure with preserved ejection fraction (HFpEF). Working with AstraZenecas Cardiovascular, Renal and Metabolism team, they will initially establish a new in vitro model using Novohearts proprietary 3D human ventricular cardiac organoid chamber (hvCOC), also known as the human heart-in-a-jar.

Overall, we dont recommend buying your sweetheart a heart in a jar. Go with the classicschocolates or flowers, instead.

BioSpace source:

https://www.biospace.com/article/valentine-s-day-matters-of-the-heart-biopharma-style

See original here:
Valentine's Day Matters of the Heart, Biopharma-Style - PharmaLive

Commentary: COVID-19 crisis reveals the extraordinary promise of bioengineering – CNA

BEIJING: They say that science is about knowing and engineering is about doing.

But the rise of artificial intelligence, big data and the Internet of Things can help us both know more and do better when it comes to improving lives worldwide.

Bioengineering, or combining engineering and medicine through emerging technologies, holds enormous promise for tackling disease, controlling pandemics and promotinghealthy lives.

The rapid mobilisation in China and elsewhere to control the outbreak of COVID-19 has showcased the range of new innovations that were unavailable even just a few years ago to help deal with a global health emergency.

TRACKING THE SPREAD

Engineers at technology company Alibaba, for example, developed anopen-source platformfor tracking the spread of COVID-19, to help health authorities prevent and prepare for new cases.

By gathering more data, governments and agencies can take more informed decisions about travel restrictions, hygiene measures and medical provisions to better protect the public and minimise the threat.

Such a tool could also be harnessed to help prevent future outbreaks as part of a One Health model thatmonitors animal healthand disease spread to predict when and how animal-borne infections might jump the species barrier to people.

Baidu, another technology company, has also developed an algorithm for predicting coronaviruss biomolecular structure to accelerate research into a vaccine.

Honing such a process could help speed up the development of vaccines against other existing and emerging diseases, meaning immunity could be offered more quickly before an outbreak takes hold.

Computer engineering has a long tradition of using an open-source model, which not only allows players in the private sector to benefit from each other, but also enables the public sector to benefit from market-driven innovation to help manage social wellbeing.

Just in the past few weeks, my alma mater, Nankai University, open-sourced analytic software for infection prediction, showing scientists and engineers across both public and private sectors collaborating to fight against a common threat to mankind.

CONTAINING THE EPIDEMIC

Finally, advances in bioengineering have also provided emergency infrastructure to help both contain the epidemic and treat those affected.

The speciality 1,000-bedfield hospitalbuilt in just 10 days in Wuhan was a feat of engineering willpower, and a case study for rapidly delivered infrastructure.

As well as prefabricated units, the hospital incorporated specialised ventilation systems and quarantine wards, which offer useful lessons for other regions coping with an outbreak of infectious disease, as well as other humanitarian situations.

Meanwhile, the use ofrobotsto deliver medicines and food to quarantined patients in Hangzhou and other cities in China have helped reduce the risk of infection among medical staff, and limit the spread of disease, while also ensuring that patients needs are met.

INHERENT CHALLENGES

Necessity is the mother of invention, and many of these solutions have come to the fore because the world is facing new and evolving challenges.

With China's recent reforms and economic growth, lifting hundreds of millions of people out of poverty, the demand for health services has become more intense, providing huge impetus for the development of bioengineering.

Between 2010 and 2018, investment in biomedical research and development more than doubled, alongside the rise of digital technology.

Internet companies, large and small, are using software that incorporates computer vision technology to serve community doctors and help them asses test results faster and more accurately, for example.

However, the current COVID-19 outbreak also exposes the gap between bioengineering development, and growing healthcare demands.

Governments and health authorities need to invest further in research and development, but more importantly, institutions need to foster inter-disciplinary research to allow new innovations that cross the divisions between traditional disciplines like medicine and engineering.

At the same time, there are also inherent challenges to overcome in the adoption of new biomedical technology itself.

Codedgender biasesin digital assistants like Siri, for example, risk reinforcing social behaviours and attitudes, while technologies such asdronesraise issues including privacy, surveillance and individual freedom.

Health mapping using algorithms, for example, should not infringe the privacy of individuals, and measures are needed to ensure that data gathered on the spread of illness does not engender discrimination or even racism.

And the use of automatons in healthcare also has social implications when it comes to the emotional and pastoral care often provided by human nurses and doctors.

Addressing these kinds of challenges is not easy but it must start with engineers, regulators and governments establishingconsensusaround ethical principles of fairness, for example, and then converting this into measurable technical standards to ensure responsible conduct.

With every new development in science and technology, we must ensure the risks of unintended consequences are mitigated to help meet the UNs goals of achieving a better, fairer life for everyone by 2030.

The COVID-19 epidemic has been a reminder of how globalisation has compounded public health issues, increasing the speed of disease spread and health risks, on the one hand.

Onthe other,it reminds us how important global efforts are to enhance our engineering capacity with powerful new tools to face the challenges of tomorrow.

If developed and adopted responsibly, smart bioengineering can help not only improve lives but save them as well.

Downloadourappor subscribe to our Telegram channel for the latest updates on the coronavirus outbreak:https://cna.asia/telegram

Gong Ke is president of the World Federation of Engineering Organizations (WFEO).

See original here:
Commentary: COVID-19 crisis reveals the extraordinary promise of bioengineering - CNA

Quadram unveils lead for Food Innovation and Health Research programme – Business Weekly

Professor Martin Warren has been appointed as the new lead for the Quadram Institutes Food Innovation and Health science programme on the Norwich Research Park.

A Professor of Biochemistry at the University of Kents School of Biosciences, Martin was awarded a BBSRC Professorial Fellowship to work on the bioengineering of complex metabolic pathways and in 2018 gained a Royal Society Industrial Fellowship.

Prof. Warren will retain his role at the University of Kent on a part-time basis, as well as an affiliation with the University of East Anglia.

Quadram Institute director Prof. Ian Charles said: Im delighted to be able to announce Martin Warrens appointment as lead for our Food Innovation and Health research programme.

His research interest in vitamin B12 forms an important part of our research at the Quadram Institute and he joins at an opportune moment as we start looking ahead developing our science strategy.

After completing his PhD studies, Prof. Warren moved in 1989 to Texas A & M University, where he worked as a research associated with Prof. Ian Scott FRS on vitamin B12 biosynthesis.

In 2007 he was awarded a BBSRC Professorial Fellowship to work on the bioengineering of complex metabolic pathways.

The rest is here:
Quadram unveils lead for Food Innovation and Health Research programme - Business Weekly

Government to open 2 fruit processing factories – Daily Monitor

By ISAAC OTWII

Government is set to commission two more fruit processing factories in Nwoya and Yumbe districts in June, an official has said.Mr Daniel Mabirizi, the planning, monitoring and evaluation officer at National Agriculture Advisory Services (Naads) secretariat, said the government is commissioning the factories to increase processing facilities in the country.We have been supporting production over a period of time. Consequently, this has led to the need to support farmers at the upper end of the value chain, he said on Tuesday.

Mr Mabirizi said the facilities set for commissioning are Yumbe Mango Fruit Processing Factory, with a capacity of five metric tonnes per hour and Kayunga Fruit Processing Plant. Kayunga factory has a capacity of 600kgs per hour.

In 2017, government encouraged farmers in Nwoya District to grow citrus fruits, mangoes and cassava with a pledge that there would be ready market after the completion of a Shs8.5 billion mango processing factory.

Naads and Uganda Development Corporation (UDC) then signed a memorandum of understanding with mango farmers in Yumbe District under their umbrella association Aringa Fruit Farmers Cooperative Society Ltd (AFFCSL). This was to establish a five-metric tonne per-hour fruit processing factory in the area under a public sector initiative. The project is being undertaken by FoNuS, a company owned by Makerere University lecturers from the School of Food Technology, Nutrition and Bioengineering.

Mr Mabirizi said the installation of the equipment is ongoing at the two facilities pending commissioning in June. Mr Patrick Alip, the agricultural officer in charge of Operation Wealth Creation in Lira District, said fruit farmers in Lira are demotivated after they were turned down by authorities at Soroti Fruit Factory.

Lira fruit producers association went to Soroti Fruit Factory to look for market for their fruits and they were told the variety they had was of low quality, he said.Soroti Fruit Factory was launched in April 2019 to tap into the abundant citrus fruits for commercial production of oranges and mangoes. However, the joy of farmers, who had anticipated to reap from the sale of their produce, has since died out due to lack of market for the fruits. Between November 2019 and January, more farmers a cross Teso watched in disbelief their fruits got rotten.

editorial@ug.nationmedia.com

See the original post here:
Government to open 2 fruit processing factories - Daily Monitor

World’s smartest child wants to study in Israel – Ynetnews

A Belgian child prodigy who is the world's youngest person to receive an undergraduate degree is eager to continue his education in Israel.

Israeli ambassador to Belgium with Laurent Simons

(Photo: Israeli Embassy, Brussels)

Nine-year-old Laurent Simons of Belgium has approached the Israeli embassy in Brussels, saying he would like to explore his possibilities for advanced studies in Israel.

Laurent is especially interested in biotechnology, medicine, and bioengineering, and hopes to study these subjects in tandem so that he can fulfill his dream of designing prosthetic organs when he grows up.

Earlier this week, his parents met with Ambassador Emmanuel Nahshon.

They said they had heard good things about academic studies in Israel and believe their son would thrive in his career and enjoy a community suitable for a ten-year-old boy.

Laurent himself expressed an interest to study various scientific fields, but would first like to master the Hebrew language.

Nahshon told the Simons family that he would convey their interest to universities in Israel.

"It is a source of pride that this child has chosen to study in Israel," Nahshon said. "It shows he is not only a genius but also really smart."

Though they have never visited Israel, Laurent's family has heard about its beauty and advanced high-tech industry, and say they are excited at the prospect of seeing it.

Laurent's undergraduate degree is in electronic engineering from the Eindhoven University of Technology and he intends to advance directly to a Ph.D. program.

See the original post here:
World's smartest child wants to study in Israel - Ynetnews

Radiology expert notches $250K from Amazon, Heart Association for speedier MRI interpretation – Radiology Business

A Seattle-based radiology professor has scored a $250,000 award from Amazon and the American Heart Association for harnessing artificial intelligence to vastly speed up MRI read times.

Chun Yuan, PhD, and colleagues beat out the competition by utilizing cloud-computing tools and AI to detect and predict blocked arteries and cardiovascular risk through magnetic resonance knee scans. Their solution helped reduce the time to read an MRI from four hours by a human radiologist down to just seven minutes using a computer program, according to an AHA announcement.

The especially exciting thing about this research is that we are able to use our technology to detect diseased blood vessels in knee images that were not acquired with that in mind, as well as using artificial intelligence to greatly shorten the time it takes to review these images, Yuan, who teaches radiology and bioengineering at the University of Washington, said in a statement.

The rest is here:
Radiology expert notches $250K from Amazon, Heart Association for speedier MRI interpretation - Radiology Business

ETU "LETI" is among the leaders in the seasonal school promotion – QS WOW News

St. Petersburg Electrotechnical University LETI has taken one of the leading places among Russian universities in terms of the number of international students enrolled in summer and winter school programs.

The results of a study on the promotion of seasonal schools conducted by experts of the Peoples Friendship University of Russia (Moscow) were published. According to the study, Peter the Great St.Petersburg Polytechnic University, ETU LETI, RUDN University, and the Higher School of Economics hold the leading positions in the number of international students enrolling in summer and winter school programs and website content with detailed information on the areas of study among Russian universities.

Also, experts highlighted the number of multilingual versions of school pages on the university websites: ETU LETI has eight languages, the same at Kazan Federal University, and RUDN University and SPbPU have three languages each. The pages of universities provide information on contact persons, the cost of courses, widespread cultural and leisure program. At the same time, experts noted a clear, convenient, and user-friendly interface.

Today, St. Petersburg Electrotechnical University LETI has ten areas of seasonal school programs in English and five in Russian.

In 2019, the university hosted the first winter English-taught professional schools; 75 students from Algeria, Argentina, Afghanistan, Bangladesh, Belgium, Ghana, Germany, Egypt, India, Indonesia, Iran, Spain, Kazakhstan, Cote dIvoire, Latvia, Libya, Myanmar, Nigeria, Pakistan, Palestine, Peru, Russia, Syria, USA, Tanzania, Tunisia, and Ecuador took part in it.

Schools worked from January 21 to February 3 in five areas, namely Bioengineering Systems and Technologies, Mechatronics and Robotics, Intercultural Communication in Business, and Gems of Russian Culture in the Russian Language. Participants in winter schools were able to combine the acquisition of professional skills with a cultural program. Students got acquainted with world-famous sites of the Capital of the North, the Hermitage Museum, Peter and Paul Fortress, and the laboratory museum ofAlexander Popov, inventor of the radio, first elected director of Electrotechnical Institute, Tsarskoye Selo, which used to be an imperial countryside residence, and the New Holland Island skating rink.

Our seasonal school programs are based on unique content. We are not just opening schools that all universities in Russia and the world have. We open schools in exclusive areas that are in demand in the global scientific and educational environment. One of such demanded schools is Heritage Science, which involves specialists from the Russian Museum and the Hermitage and Italian colleagues. This winter we plan to launch a new seasonal school, Automotive Energy.

Also, experts highlighted the number of multilingual versions of school pages on the university websites: ETU LETI has eight languages, the same at Kazan Federal University, and RUDN University and SPbPU have three languages each. The pages of universities provide information on contact persons, the cost of courses, widespread cultural and leisure program. At the same time, experts noted a clear, convenient, and user-friendly interface.

Today, St. Petersburg Electrotechnical University LETI has ten areas of seasonal school programs in English and five in Russian.

In 2019, the university hosted the first winter English-taught professional schools; 75 students from Algeria, Argentina, Afghanistan, Bangladesh, Belgium, Ghana, Germany, Egypt, India, Indonesia, Iran, Spain, Kazakhstan, Cote dIvoire, Latvia, Libya, Myanmar, Nigeria, Pakistan, Palestine, Peru, Russia, Syria, USA, Tanzania, Tunisia, and Ecuador took part in it.

Schools worked from January 21 to February 3 in five areas, namely Bioengineering Systems and Technologies, Mechatronics and Robotics, Intercultural Communication in Business, and Gems of Russian Culture in the Russian Language. Participants in winter schools were able to combine the acquisition of professional skills with a cultural program. Students got acquainted with world-famous sites of the Capital of the North, the Hermitage Museum, Peter and Paul Fortress, and the laboratory museum ofAlexander Popov, inventor of the radio, first elected director of Electrotechnical Institute, Tsarskoye Selo, which used to be an imperial countryside residence, and the New Holland Island skating rink.

Our seasonal school programs are based on unique content. We are not just opening schools that all universities in Russia and the world have. We open schools in exclusive areas that are in demand in the global scientific and educational environment. One of such demanded schools is Heritage Science, which involves specialists from the Russian Museum and the Hermitage and Italian colleagues. This winter we plan to launch a new seasonal school, Automotive Energy.

40 organizations participated in the analysis of the websites of Russian universities in terms of mechanisms for promoting summer and winter schools (including 21 universities of the project 5-100), and 4 educational centers that conduct summer schools for children based on summer health camps with many years of successful experience of work with children from foreign countries.

The group of universities includes institutions that have competitive and demanded summer and winter schools programs in the education market, high rates in international ratings, experience in recruiting international students, modern equipment, and can diversify educational services given the market demands.

In 2018, 8502 students took part in summer schools in 417 universities of Russia. St. Petersburg took first place in Russia in the number of students who attended summer schools with 2091 people.

Originally posted here:
ETU "LETI" is among the leaders in the seasonal school promotion - QS WOW News

University of Queensland asked to rapidly develop coronavirus vaccine – Australian Hospital + Healthcare Bulletin

The University of Queensland (UQ) has been asked to develop a vaccine for the coronavirus that could be available worldwide in as little as six months.

The Coalition for Epidemic Preparedness Innovations (CEPI) has requested the university use its recently developed rapid response technology to develop a new vaccine.

The Head of UQs School of Chemistry and Molecular Biosciences, Professor Paul Young, said UQ has novel technology for the rapid generation of new vaccines from the knowledge of a viruss genetic sequence information.

The team hopes to develop a vaccine over the next six months, which may be used to help contain this outbreak, he said.

The vaccine would be distributed to first responders, helping to contain the virus from spreading around the world.

Dr Keith Chappell, from UQs School of Chemistry and Molecular Biosciences and the Australian Institute for Bioengineering and Nanotechnology, said the key to the speedy development of this potential vaccine is molecular clamp technology, invented by UQ scientists and patented by UniQuest.

The University of Queenslands molecular clamp technology provides stability to the viral protein that is the primary target for our immune defence, he said.

The technology has been designed as a platform approach to generate vaccines against a range of human and animal viruses and has shown promising results in the laboratory targeting viruses such as influenza, Ebola, Nipah and MERS coronavirus.

UQ Vice-Chancellor and President Professor Peter Hj AC said the fluidity of the current outbreak represents a significant challenge to the international community.

There is a lot that is still unknown regarding how easily the virus is able to be transmitted between humans, he said.

Working with CEPI, The University of Queensland is using its vaccine technology to respond to this global health challenge.

Image caption: (LR) Professor Paul Young, Dr Keith Chappell and Dr Dan Watterson. Image courtesy of The University of Queensland.

See the original post here:
University of Queensland asked to rapidly develop coronavirus vaccine - Australian Hospital + Healthcare Bulletin

Invisible Ink Could Reveal whether Kids Have Been Vaccinated – Scientific American

Keeping track of vaccinations remains a major challenge in the developing world, and even in many developed countries, paperwork gets lost, and parents forget whether their child is up to date. Now a group of Massachusetts Institute of Technology researchers has developed a novel way to address this problem: embedding the record directly into the skin.

Along with the vaccine, a child would be injected with a bit of dye that is invisible to the naked eye but easily seen with a special cell-phone filter, combined with an app that shines near-infrared light onto the skin. The dye would be expected to last up to five years, according to tests on pig and rat skin and human skin in a dish.

The systemwhich has not yet been tested in childrenwould provide quick and easy access to vaccination history, avoid the risk of clerical errors, and add little to the cost or risk of the procedure, according to the study, published Wednesday in Science Translational Medicine.

Especially in developing countries where medical records may not be as complete or as accessible, there can be value in having medical information directly associated with a person, says Mark Prausnitz, a bioengineering professor at the Georgia Institute of Technology, who was not involved in the new study. Such a system of recording medical information must be extremely discreet and acceptable to the person whose health information is being recorded and his or her family, he says. This, I think, is a pretty interesting way to accomplish those goals.

The research, conducted by M.I.T. bioengineers Robert Langer and Ana Jaklenec and their colleagues, uses a patch of tiny needles called microneedles to provide an effective vaccination without a teeth-clenching jab. Microneedles are embedded in a Band-Aid-like device that is placed on the skin; a skilled nurse or technician is not required. Vaccines delivered with microneedles also may not need to be refrigerated, reducing both the cost and difficulty of delivery, Langer and Jaklenec say.

Delivering the dye required the researchers to find something that was safe and would last long enough to be useful. Thats really the biggest challenge that we overcame in the project, Jaklenec says, adding that the team tested a number of off-the-shelf dyes that could be used in the body but could not find any that endured when exposed to sunlight. The team ended up using a technology called quantum dots, tiny semiconducting crystals that reflect light and were originally developed to label cells during research. The dye has been shown to be safe in humans.

The approach raises some privacy concerns, says Prausnitz, who helped invent microneedle technology and directs Georgia Techs Center for Drug Design, Development and Delivery. There may be other concerns that patients have about being tattooed, carrying around personal medical information on their bodies or other aspects of this unfamiliar approach to storing medical records, he says. Different people and different cultures will probably feel differently about having an invisible medical tattoo.

When people were still getting vaccinated for smallpox, which has since been eradicated worldwide, they got a visible scar on their arm from the shot that made it easy to identify who had been vaccinated and who had not, Jaklenec says. But obviously, we didnt want to give people a scar, she says, noting that her team was looking for an identifier that would be invisible to the naked eye. The researchers also wanted to avoid technologies that would raise even more privacy concerns, such as iris scans and databases with names and identifiable data, she says.

The work was funded by the Bill & Melinda Gates Foundation and came about because of a direct request from Microsoft founder and philanthropist Bill Gates himself, who has been supporting efforts to wipe out diseases such as polio and measles across the world, Jaklenec says. If we dont have good data, its really difficult to eradicate disease, she says.

The researchers hope to add more detailed information to the dots, such as the date of vaccination. Along with them, the team eventually wants to inject sensors that could also potentially be used to track aspects of health such as insulin levels in diabetics, Jaklenec says.

This approach is likely to be one of many trying to solve the problem of storing individuals medical information, says Ruchit Nagar, a fourth-year student at Harvard Medical School, who also was not involved in the new study. He runs a company, called Khushi Baby, that is also trying to create a system for tracking such information, including vaccination history, in the developing world.

Working in the northern Indian state of Rajasthan, Nagar and his team have devised a necklace, resembling one worn locally, which compresses, encrypts and password protects medical information. The necklace uses the same technology as radio-frequency identification (RFID) chipssuch as those employed in retail clothing or athletes race bibsand provides health care workers access to a mothers pregnancy history, her childs growth chart and vaccination history, and suggestions on what vaccinations and other treatments may be needed, he says. But Nagar acknowledges the possible concerns all such technology poses. Messaging and cultural appropriateness need to be considered, he says.

Read more:
Invisible Ink Could Reveal whether Kids Have Been Vaccinated - Scientific American

In the Spotlight: Using engineering to improve patients’ lives – Scope

Meet Ross Venook, PhD, assistant director of engineering at the Stanford Byers Center for Biodesign and a lecturer in bioengineering. An electrical engineer by training, his work has focused on building and applying new types of MRI hardware, as well as MRI safety for patients with implanted medical devices. I talked to him about his work in and out of Stanford and the power of engineering to solve medical problems:

How long have you been at Stanford?

I was at Stanford as an undergraduate and continued straight through for my masters and PhD, all in electrical engineering. After that, I left to become a research and development engineer at Boston Scientific, a large medical device manufacturing company. I still work one day a week in the neuromodulation division there, doing MRI safety-related projects.

I also develop and lead courses for undergraduate and graduate students, and run the engineering parts of the Biodesign program, including our medtech-focused makerspace.

What are some projects you've worked on?

As a graduate student, I worked on new types of MRI hardware, including a lower-cost "prepolarized" MRI system. During my Biodesign fellowship, we worked on areas ranging from better cardiac ablation lesions to a way to address stress urinary incontinence without causing chronic tissue effects.

At Boston Scientific, I have helped to test and ensure safety under MRI for products ranging from surgical staples to pacemakers to spinal cord stimulators, and most recently, deep brain stimulators. I am also advising a company that started out of a Biodesign class that now has a product in the neonatal space -- a mechanism to better hold umbilical catheters in place in premature babies.

Why did you go into science and medicine?

In elementary school, I had the rare opportunity to have a very rich science education that was focused on inquiry, which really fostered my interest in science as a whole. Surprisingly, I actually didn't know what an engineer was or what they did until late into high school. When I did find out, I fell in love because it was an application of science.

How have your career goals changed over time?

When I was an undergrad, I considered pursuing medicine as a career. When I decided to go to graduate school in engineering instead, I opted to study medical imaging and work on technologies I felt could have clinical impact.

The Stanford Biodesign program really transformed my perspective on what could be possible for my career. I got to spend time with clinicians in the hospital and in operating rooms. I learned a lot about how medicine works, and the Biodesign needs-first approach really resonated with me: understanding the clinical challenge before aiming bioengineering toward what was really needed from a patient perspective.

I now enjoy the opportunity to help students learn how to design and build their own projects with real-world medical applications.

What is the biggest challenge in the health technology field?

There's more pressure on innovators to deliver new therapies that work better and also are able to pay for themselves from day one. That's hard. That creates challenges in the pipeline for people trying to do innovative medical work and get funding for early-stage ideas. I think the move toward value-based health care is important, but that doesn't mean that it's easy.

What's your life like outside of work?

My wife and I live in Millbrae with our two boys. She works at Genentech on cancer therapeutics, and loves the impact of the work she does. Our sons are 8 and 10, so days are filled with a lot of baseball, soccer, or basketball these days. I coach their teams a little bit, and working with younger kids is fun.

How do you unwind?

I love to spend time outdoors, whether it's hiking or biking, playing sports or just walking to the Caltrain on my commute.

What was the best trip you've taken recently?

One of my most recent fun trips was with our family to Zion National Park. We camped and hiked with the families of two of my closest friends from grad school. We came from different spots in the U.S. to meet in Zion and enjoy the outdoors together with our kids, and I hope we can figure out how to have another national park adventure soon.

Photos by Norbert von der Groeben, top, and Rod Searcey, middle

Read more:
In the Spotlight: Using engineering to improve patients' lives - Scope

USA Mixed Tocopherol Market 2019 -2026 | Competitive Landscape, Trends And Opportunities – Industry Mirror

In this report, our team research the USA Mixed Tocopherol market by type, application, region and manufacturer (2014-2020) and forcast 2021-2026. For the region, type and application, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers sales, price, revenue, cost and gross profit and their changes. Whats more, we will display the main consumers, raw material manufacturers, distributors, etc.

Request for Sample with [emailprotected]https://www.researchtrades.com/request-sample/1794091

Geographically, this report split USA into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Mixed Tocopherol for these regions, from 2014 to 2026 (forecast), includingNortheastMidwestSouthWest

USA Mixed Tocopherol market competition by top manufacturers/players, with Mixed Tocopherol sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players includingBASFDSMB&D Nutritional ingredientsAmerican River Nutrition, Inc.COFCO Tech BioengineeringFenchemBiotekArcher Daniels MidlandUNIQUEThorne Research Inc.Wilmar International LimitedMetabolic MaintenanceNatural Factors Inc.

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split intoAlpha TocopherolBeta TocopherolGamma TocopherolDelta Tocopherol

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Mixed Tocopherol for each application, includingAnimal Feed NutritionCosmeticsPharmaceyticalsFood and Beverage

Table of Contents

1 Report Overview1.1 Definition and Specification1.2 Report Overview1.2.1 Manufacturers Overview1.2.2 Regions Overview1.2.3 Type Overview1.2.4 Application Overview1.3 Industrial Chain1.3.1 Mixed Tocopherol Overall Industrial Chain1.3.2 Upstream1.3.3 Downstream1.4 Industry Situation1.4.1 Industrial Policy1.4.2 Product Preference1.4.3 Economic/Political Environment1.5 SWOT Analysis2 Market Analysis by Types2.1 Overall Market Performance(Volume)2.1.1 Alpha Tocopherol Market Performance (Volume)2.1.2 Beta Tocopherol Market Performance (Volume)2.1.3 Gamma Tocopherol Market Performance (Volume)2.1.4 Delta Tocopherol Market Performance (Volume)2.2 Overall Market Performance(Value)2.2.1 Alpha Tocopherol Market Performance (Value)2.2.2 Beta Tocopherol Market Performance (Value)2.2.3 Gamma Tocopherol Market Performance (Value)2.2.4 Delta Tocopherol Market Performance (Value)3 Market Assessment by Application3.1 Overall Market Performance (Volume)3.1.1 Animal Feed Nutrition Market Performance (Volume)3.1.2 Cosmetics Market Performance (Volume)3.1.3 Pharmaceyticals Market Performance (Volume)3.1.4 Food and Beverage Market Performance (Volume)4 Manufacturers Profiles/Analysis4.1 BASF4.1.1 BASF Profiles4.1.2 BASF Product Information4.1.3 BASF Mixed Tocopherol Business Performance4.1.4 BASF Mixed Tocopherol Business Development and Market Status4.2 DSM4.2.1 DSM Profiles4.2.2 DSM Product Information4.2.3 DSM Mixed Tocopherol Business Performance4.2.4 DSM Mixed Tocopherol Business Development and Market Status4.3 B&D Nutritional ingredients4.3.1 B&D Nutritional ingredients Profiles4.3.2 B&D Nutritional ingredients Product Information4.3.3 B&D Nutritional ingredients Mixed Tocopherol Business Performance4.3.4 B&D Nutritional ingredients Mixed Tocopherol Business Development and Market Status4.4 American River Nutrition, Inc.4.4.1 American River Nutrition, Inc. Profiles4.4.2 American River Nutrition, Inc. Product Information4.4.3 American River Nutrition, Inc. Mixed Tocopherol Business Performance4.4.4 American River Nutrition, Inc. Mixed Tocopherol Business Development and Market Status4.5 COFCO Tech Bioengineering4.5.1 COFCO Tech Bioengineering Profiles4.5.2 COFCO Tech Bioengineering Product Information4.5.3 COFCO Tech Bioengineering Mixed Tocopherol Business Performance4.5.4 COFCO Tech Bioengineering Mixed Tocopherol Business Development and Market Status4.6 FenchemBiotek4.6.1 FenchemBiotek Profiles4.6.2 FenchemBiotek Product Information4.6.3 FenchemBiotek Mixed Tocopherol Business Performance4.6.4 FenchemBiotek Mixed Tocopherol Business Development and Market Status4.7 Archer Daniels Midland4.7.1 Archer Daniels Midland Profiles4.7.2 Archer Daniels Midland Product Information4.7.3 Archer Daniels Midland Mixed Tocopherol Business Performance4.7.4 Archer Daniels Midland Mixed Tocopherol Business Development and Market Status4.8 UNIQUE4.8.1 UNIQUE Profiles4.8.2 UNIQUE Product Information4.8.3 UNIQUE Mixed Tocopherol Business Performance4.8.4 UNIQUE Mixed Tocopherol Business Development and Market Status4.9 Thorne Research Inc.4.9.1 Thorne Research Inc. Profiles4.9.2 Thorne Research Inc. Product Information4.9.3 Thorne Research Inc. Mixed Tocopherol Business Performance4.9.4 Thorne Research Inc. Mixed Tocopherol Business Development and Market Status4.10 Wilmar International Limited4.10.1 Wilmar International Limited Profiles4.10.2 Wilmar International Limited Product Information4.10.3 Wilmar International Limited Mixed Tocopherol Business Performance4.10.4 Wilmar International Limited Mixed Tocopherol Business Development and Market Status4.11 Metabolic Maintenance4.12 Natural Factors Inc.

Get the buy [emailprotected]https://www.researchtrades.com/checkout/1794091

..

About UsResearch Trades has a team of experts who work on providing exhaustive analysis pertaining to market research on a global basis. This comprehensive analysis is obtained by a thorough research and study of the ongoing trends and provides predictive data regarding the future estimations, which can be utilized by various organizations for growth purposes.

Contact Us:call us : +1 6269994607 (US)/+91 7507349866 (IND)skype id: researchtradesconEmail: [emailprotected]web: http://www.researchtrades.com

This post was originally published on Industry Mirror

Go here to see the original:
USA Mixed Tocopherol Market 2019 -2026 | Competitive Landscape, Trends And Opportunities - Industry Mirror

ASME Launching Nerem Medal – Research Horizons

Posted May 9, 2017 Atlanta, GA

Bob Nerem has won some of the top awards and honors in his field, recognitions for his dedication and accomplishments over a long career as a trailblazing bioengineer. But this summer, hell receive the kind of honor that will outlast him, when the American Society of Mechanical Engineers (ASME) commits his likeness to bronze.

ASME has established the Robert M. Nerem Education and Mentorship Medal to recognize individuals who play a role in influencing engineering careers in the growing field of bioengineering, said K. Keith Roe, president of the society. A key criteria is mentoring in the form of activities that are innovative above and beyond what is normally seen.

That would be Nerem, founding director of the Petit Institute for Bioengineering and Bioscience at the Georgia Institute of Technology. He is a member of the National Academy of Engineers (NAE) and one of only three bioengineers to receive the Founders Award from that organization. Hes also a member of the National Academy of Medicine, and a Fellow of the American Academy of Arts and Sciences.

Nerem was instrumental in launching the American Institute for Medical and Biological Engineering (AIMBE), serving as its founding president, and helped establish the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the newest member of the National Institutes of Health (NIH). He also belongs to both the Royal Swedish Academy of Engineering Sciences and the Polish Academy of Sciences, and holds honorary doctorates from the University of Paris, Imperial College of London, and the Illinois Institute of Technology.

More significant than any scholarly or research achievement for Nerem has been his commitment to mentorship. He started the Petit Undergraduate Research Scholars program, to help develop the next generation of bioengineering and bioscience researchers with a full-year research experience. In 17 years, the program has supported more than 250 scholars from area colleges and universities, including Agnes Scott, Emory, Georgia State, Georgia Tech, Morehouse, and Spelman.

Four years ago saw the beginning of what Nerem considers his crowning achievement Project ENGAGES. Nerem spearheaded the establishment of this program, which introduces under-represented minority high school students to careers in science and engineering, bringing these young scholars into Petit Institute labs for a year-round research experience. So far, 85 students have participated, and nearly every graduate so far has gone on to college (one chose to serve in the military first).

The new Nerem Medal will be granted through ASMEs bioengineering division, says Ross Ethier, interim chair of the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory.

We already have a medal within our division for research excellence, and theres a young investigators medal, notes Ethier, who will become president of the bioengineering division July 1. Another important part of what we do as researchers and educators is mentoring, and theres no one better who exemplifies this aspect of what we do than Bob Nerem. Who better to name a medal after?

Its kind of a big deal, the medal. Establishing it required approval of the bioengineering division leadership (it was unanimous, Ethier says) and also approval of the ASME Board of Governors.

The bottom line is, this medal is really about Bob and honoring his many contributions to the community, his mentorship of junior researchers, and his leadership over the years, Ethier says.

ASMEs newest major award will be launched this summer at the Summer Biomechanics, Bioengineering, and Biotransport Conference (the annual SB3C), June 21-24, in Tucson, Arizona. The well-traveled Nerem, of course, plans to be there.

It is unusual to be cast in bronze, and what an amazing honor, says Nerem. The medal is nice, of course, but more important, Ive been committed to education and mentorship my entire life, and to have an award named after me in that category is very, very special.

CONTACT:

Jerry Grillo Communications Officer II Parker H. Petit Institute for Bioengineering and Bioscience

More here:
ASME Launching Nerem Medal - Research Horizons

Global Bio Decontamination Equipment Market, Forecast to 2026: Drivers, Restraints, Opportunities, Developments, Segments & Players -…

DUBLIN--(BUSINESS WIRE)--The "Global Bio Decontamination Equipment Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Bio-decontamination Equipment market is expected to reach $224.24 million by 2026 growing at a CAGR of 8.1% from 2018 to 2026.

Factors such as rise in use of these equipments in hospitals and other healthcare institutions and increasing number of government initiatives are driving the market growth. Though, the high expenses of the product, particularly powered and strict government regulations in some countries is projected to inhibit the growth of the market. Moreover, rising number of technological applications may provide ample opportunities for the market growth.

By application, pharmaceutical manufacturing segment acquired significant growth in the market owing to aging population and rising chronic and infectious diseases, the pharmaceutical producers are investing heavily in these equipments. Microbial testing and equipment decontamination can be offered as a value-added service to pharmaceutical manufacturers.

The key vendors mentioned are Bioquell, STERIS Life Science, TOMI Environmental Solutions, Fedegari Group, Howorth Air Technology, JCE Biotechnology, Weike Biological Laboratory, Tailin BioEngineering and Noxilizer.

Key Questions Answered in this Report

Key Topics Covered

1 Market Synopsis

2 Research Outline

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Bio Decontamination Equipment Market, By Product Type

5.1 Introduction

5.2 Type 1

5.3 Type 2

6 Global Bio Decontamination Equipment Market, By Type

6.1 Introduction

6.2 Room Decontamination

6.3 Chamber Decontamination

6.4 Starch Blend with PLA

6.5 Starch-Based

7 Global Bio Decontamination Equipment Market, By Product

7.1 Introduction

7.2 Isolator

7.3 Steam Sterilizers

7.4 Pure Steam & Water Systems

7.5 Washers & Dryers

7.6 VHP Sterilization & Biodecontamination

7.7 Transfer Airlocks

7.8 Vaprox Hydrogen Peroxide

7.9 Incubators

7.10 Containers

8 Global Bio Decontamination Equipment Market, By Application

8.1 Introduction

8.2 Bioscience Research

8.3 Pharmaceutical Manufacturing

8.4 Life Science Industry

8.5 Hospital & Healthcare

8.6 Biomedical

8.7 Vitro Fertilization (IVF)

8.8 Animal Care

8.9 Biotechnological

9 Global Bio Decontamination Equipment Market, By Geography

9.1 Introduction

9.2 North America

9.3 Europe

9.4 Asia-Pacific

9.5 South America

9.6 Middle East & Africa

10 Strategic Benchmarking

11 Vendors Landscape

11.1 Bioquell

11.2 STERIS Life Science

11.3 TOMI Environmental Solutions

11.4 Fedegari Group

11.5 Howorth Air Technology

11.6 JCE Biotechnology

11.7 Weike Biological Laboratory

11.8 Tailin BioEngineering

11.9 Noxilizer

For more information about this report visit https://www.researchandmarkets.com/r/1q2xof

Follow this link:
Global Bio Decontamination Equipment Market, Forecast to 2026: Drivers, Restraints, Opportunities, Developments, Segments & Players -...